Celldex Therapeutics, Inc. (CLDX) Investor Relations Documents

Celldex Therapeutics, Inc. (CLDX) investor relations documents from the company's IR site: 1 presentation, 39 press releases; latest deck 2026-08-14. Read in-app with summaries. First-party data.

Celldex Therapeutics Corporate Presentation: Celldex's barzolvolimab shows strong Phase 2 results for chronic urticaria and inducible urticaria, with Phase 3 CSU data expected Sept/Oct 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-14PresentationCelldex Therapeutics Corporate Presentation
2026-08-06Press releaseDownload PDF
2026-08-06Press releaseCelldex Reports Second Quarter Financial Results and Provides Corporate Update
2026-07-21Press releaseDownload PDF
2026-07-21Press releaseCelldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
2026-07-15Press releaseDownload PDF
2026-07-15Press releaseCelldex Announces Planned Transition of Chief Financial Officer
2026-06-14Press releaseDownload PDF
2026-06-14Press releaseDownload PDF
2026-06-14Press releaseCelldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy
2026-06-14Press releaseCelldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Pati
2026-06-10Press releaseDownload PDF
2026-06-10Press releaseCelldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 Europea
2026-05-07Press releaseDownload PDF
2026-05-07Press releaseCelldex Reports First Quarter Financial Results and Provides Corporate Update
2026-04-13Press releaseDownload PDF
2026-04-13Press releaseCelldex to Present at Upcoming Investor Conference
2026-04-06Press releaseDownload PDF
2026-04-06Press releaseCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to P
2026-04-01Press releaseDownload PDF
2026-04-01Press releaseDownload PDF
2026-04-01Press releaseCelldex Announces Proposed Public Offering of Common Stock
2026-04-01Press releaseCelldex Announces Pricing of $300 Million Public Offering of Common Stock
2026-03-27Press releaseDownload PDF
2026-03-27Press releaseCelldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Der
2026-03-01Press releaseDownload PDF
2026-03-01Press releaseCelldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Expos
2026-02-27Press releaseDownload PDF
2026-02-27Press releaseCelldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (C
2026-02-25Press releaseDownload PDF
2026-02-25Press releaseDownload PDF
2026-02-25Press releaseCelldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
2026-02-25Press releaseCelldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontan
2026-02-23Press releaseDownload PDF
2026-02-23Press releaseCelldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Di
2026-02-09Press releaseDownload PDF
2026-02-09Press releaseCelldex to Present at Upcoming Investor Conferences
2025-12-09Press releaseDownload PDF
2025-12-09Press releaseCelldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
Press releaseCelldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update

CLDX overview · CLDX earnings · CLDX financials · CLDX KPIs · CLDX documents · CLDX ownership · CLDX peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.